文献速递肝肾功能剂量调整特殊人群用药

射血分数降低心衰合并终末期肾病腹膜透析患者的沙库巴曲缬沙坦群体药代动力学

Population Pharmacokinetics of Sacubitril/Valsartan in Patients with Heart Failure and End-Stage Renal Disease Undergoing Peritoneal Dialysis.
PubMed 文献 · Clin Pharmacokinet · 2026-04-29

该前瞻性研究纳入40例心衰合并终末期肾病腹膜透析患者,构建群体药代动力学模型同时表征缬沙坦与LBQ657在血浆、尿液和腹膜透析液中的处置。去脂体重是非肾清除和暴露的关键决定因素,腹膜透析清除贡献极小,基于腹膜透析状态无需调整剂量。

要点

  • 去脂体重是缬沙坦和LBQ657非肾清除与暴露的关键协变量。
  • 腹膜透析对缬沙坦和LBQ657的清除贡献极小,无需据此调整剂量。
  • 去脂体重58.95 kg较中位42.2 kg时缬沙坦稳态AUC低54%、LBQ657低26%。

核心结论

  • 在心力衰竭合并终末期肾病腹膜透析患者中,腹膜透析对沙库巴曲缬沙坦的药代动力学影响极小,无需基于腹膜透析状态调整剂量。

研究设计与样本

  • 前瞻性研究,纳入40例心力衰竭合并终末期肾病腹膜透析患者,采集血浆、尿液和腹膜透析液样本,构建群体药代动力学模型同时表征缬沙坦和LBQ657。

主要发现

  • 采用一室模型加一阶吸收和消除,并纳入尿排泄及与腹膜透析液的双向交换,可表征缬沙坦和LBQ657的药代动力学。
  • 去脂体重是非肾清除和暴露的关键决定因素。
  • 相对中位去脂体重42.2 kg,去脂体重58.95 kg与缬沙坦稳态AUC降低54%、LBQ657稳态AUC降低26%相关。
  • 缬沙坦和LBQ657的尿排泄与腹膜透析液排泄均很小,分别不超过1%和7%。

临床怎么用

  • 在心力衰竭合并终末期肾病腹膜透析患者中使用沙库巴曲缬沙坦时,无需仅因腹膜透析状态调整剂量。
  • 去脂体重较低的患者暴露更高,临床用药时应关注该协变量对暴露的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Cardiovascular risk is markedly increased in end-stage renal disease. Although sacubitril/valsartan provides cardiovascular benefits in heart failure, evidence supporting its use in end-stage renal disease, particularly in patients undergoing peritoneal dialysis, remains limited. This study aimed to characterize the pharmacokinetics of sacubitril/valsartan in patients with heart failure and end-stage renal disease undergoing peritoneal dialysis and to determine whether dose adjustment is warranted. METHODS: In this prospective study, plasma, urine, and peritoneal dialysate samples were collected from 40 patients with heart failure and end-stage renal disease undergoing peritoneal dialysis, and population pharmacokinetic models were developed to simultaneously characterize valsartan and LBQ657 pharmacokinetic profiles across the three matrices. Covariates' effects were quantitatively evaluated using a forest plot. Renal and peritoneal dialysate excretion fractions of valsartan and LBQ657 were estimated based on population pharmacokinetic models. RESULTS: A one-compartment model with first-order absorption and elimination, incorporating urinary excretion and bidirectional exchange with peritoneal dialysate, was developed to characterize the pharmacokinetics of valsartan and LBQ657 in patients with end-stage renal disease. Fat-free mass was a key determinant of non-renal clearance and exposure for both analytes. A covariate analysis showed that, relative to the median fat-free mass (42.2 kg), a fat-free mass of 58.95 kg was associated with a 54% lower valsartan area under the concentration-time curve during steady state and a 26% lower LBQ657 area under the concentration-time curve during steady state. Urinary and peritoneal dialysate eliminations of valsartan and LBQ657 were minimal, not exceeding 1% and 7%, respectively. CONCLUSIONS: The population pharmacokinetic models for valsartan and LBQ657 adequately characterized profiles in plasma, urine, and peritoneal dialysate in patients with heart failure and end-stage renal disease undergoing peritoneal dialysis. In this special population, the impact of peritoneal dialysis was minimal, and no dose adjustment is required based on peritoneal dialysis status. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry identifier no. ChiCTR2200055924.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Jin Y, Xu N, Yang W, et al. Population Pharmacokinetics of Sacubitril/Valsartan in Patients with Heart Failure and End-Stage Renal Disease Undergoing Peritoneal Dialysis. Clin Pharmacokinet. 2026. PMID: 42053769. doi:10.1007/s40262-026-01647-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。